
“Company’s chemicals segment contributes 1/3rd to total revenues while
contribution to profit is 2/3rd. Caprolactam contributes ~70% to
chemical revenues / profits and hence company’s earnings closely follow
its Caprolactam Benzene spread. (Kindly refer to chart on next page).
On account of sharp drop in spreads, we expect GSFC to enter into
earnings degrowth phase in FY13 with each quarter reporting earnings
drop of 20%- 40%. This earnings degrowth phase along with no positive
trigger in near term is likely to keep pressure on company’s stock
price.”
“We downgrade our FY13E EPS est by 10% to Rs 65.6, which is 20% below
consensus est, on account of sharp decline in chemical segment margins.
Historically we have seen company’s stock price following its chemical
business profitability and downward pressure on chemical segment margins
is likely to keep the stock price under pressure. We downgrade our
recommendation from Accumulate to REDUCE and wait for improvement in
Caprolactam-Benzene spread. However we expect GSFC to benefit marginally
from higher ammonia prices,” says Emkay Global Financial Services
research report.
No comments:
Post a Comment